Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation  by Aerts, Hugo J.W.L. et al.
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It  was  recently  described  that  high  FDG-uptake  areas  pre-radiotherapy  largely  correspond  with  residual
metabolic-active  areas  post-radiotherapy.  Here,  an  independent  prospective  validation  of  these results
was performed  using  an  overlap-fraction  (OF)  calculation  of  various  FDG-uptake  based  thresholds.  Data
from twelve  patients  treated  at Radboud  University  Nijmegen  Medical  Center  with  lung cancer  were
analyzed.  All  patients  underwent  two  FDG-PET-CT  scans,  one  pre-radiotherapy  (pre-RT)  and  one  approx-
imately three  months  after  treatment  (post-RT).  Of the  twelve  analyzed  patients,  eight patients  showed
residual  FDG  uptake  on  the  post-RT  scan  and  were  included  for  analysis.  One  of these  patients  had  a
residue  that  was  not  clearly  distinguishable  from  the  surrounding  tissue  due  to  FDG  avid  inﬂammation.
Therefore,  seven  patients  remained  for further  analysis.  The  mean  volume  of the  residual  metabolic-
active  areas  post-RT  was 14.6 ± 10.0%  (mean  ±  SD)  of  the  mean  volume  of  the  gross  tumour  volume  (GTV)ET-CT pre-RT.  The  residual  metabolic-active  areas  largely  corresponded  with  the  pre-RT  GTV  (OF = 93.7 ±  7.2%).
The pre-RT-scan  threshold  delineations  of 34%,  40%  and  50%  of  the  SUVmax had  a  large  OF  with  the
residual  region,  86.9  ±  8.3%,  77.4  ±  8.1%  and  67.9 ± 6.8%,  respectively.  In this  independent  dataset,  we
conﬁrmed  that  the  location  of  residual  FDG-uptake  areas  after  radiotherapy  corresponds  with the  high
FDG-uptake  areas  pre-radiotherapy.  Therefore,  a pre-radiotherapy  FDG-PET-CT  scan  can potentially  be
used  for  radiotherapy  dose  redistribution.. Introduction
Lung cancer is one of the most frequent and lethal solid tumours
1]. Although the prognosis has improved, the 5-year survival is
bout 20% in locally advanced non-small cell lung cancer (NSCLC)
2,3]. While concurrent chemo-radiation improved local control
nd long-term survival compared to traditional sequential (chemo-
 radiotherapy, local tumour failure is still observed in the majority
f patients [4].  Improvements in local tumour control can be
chieved by escalating the radiation dose, where local control rates
ver 90% can be reached for tumour doses of 120 Gy [5,6]. How-
ver, the problem is that tumour dose escalation is limited by the
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radiation toxicity of normal tissues such as the lungs and the spinal
cord.
A solution to this problem may  be found in the intra-tumour
heterogeneity. It has become increasingly clear that tumour tis-
sue is often not homogeneous, but can have large spatial variations
with different biological characteristics, like perfusion, hypoxia,
cell density, proliferation and subsequent radio-resistance [7–12].
Therefore, a strategy to increase the dose to more radio-resistant
areas within the tumour, while reducing the dose to more suscep-
tible zones, can result in better local control rates with the same
healthy tissue toxicity [13].
A strategy to determine the location of the radio-resistant areas
within the tumour is the use of non-invasive imaging. Since high
pre-treatment 18F-deoxyglucose (FDG) uptake levels in the primary
tumour result in lower survival in patients with NSCLC [14–16],  we
hypothesized that the regions with high FDG uptake before treat-
Open access under the Elsevier OA license.ment identify more radio-resistant areas within the tumour. If true,
an increased survival could be expected from radiation dose redis-
tribution according to FDG uptake pre-radiotherapy. In an earlier
study, we  demonstrated that this hypothesis holds true for a group
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f NSCLC patients in MAASTRO Clinic (Maastricht, The Netherlands)
17]. Here, we report on an independent prospective dataset to
alidate that the high FDG uptake areas pre-radiotherapy identify
he residual metabolic active areas post-radiotherapy.
. Materials and methods
.1. Patient characteristics
Twelve patients of Radboud University Nijmegen Medical Cen-
er (Nijmegen, The Netherlands) with inoperable non-small cell
ung cancer (NSCLC), UICC stage II–III, eleven treated with sequen-
ial chemo-radiotherapy and one with radical radiotherapy (RT)
lone. The sequential chemo-radiotherapy schedule consisted of
–3 cycles of cisplatin and gemcitabine before the start of RT.
atients were included from June 2007 until August 2008. Mean
ge was 66.2 ± 9.5 years (range: 52–83 years). Two FDG-PET-CT
cans were available for each patient. The ﬁrst scan was  per-
ormed before start of RT while the second scan was performed
pproximately three months after the end of RT. Both scans were
erformed under similar conditions. For the patients receiving
equential chemo-radiotherapy the pre-RT scan was  performed
fter the chemotherapy. No treatment was given to any of the
atients between the end of RT and the post-RT scan.
.2. Radiotherapy simulation and planning
Patients were simulated in radiotherapy position on a CT-
imulator, multislice spiral CT scanner (Philips AcQsim, Philips,
leveland, USA) with both arms above the head. For the FDG-
ET-CT scans (Siemens/CTI, Knoxville, Tennessee, USA) was  used.
n intravenous injection of 250 MBq  FDG (Covidien, Petten, The
etherlands) was followed by 10 ml  normal saline. After a 60 min
ptake period, during which the patient was encouraged to rest,
ET-CT images were acquired.
Radiotherapy planning was performed on a Pinnacle (version
.0d; Philips Radiation Oncology System, Madison, WI,  USA), the
adiotherapy planning system routinely used which is based on a
onvolution algorithm using inhomogeneity corrections. The Gross
umour Volume (GTV) and the Planning Target Volume (PTV) were
eﬁned for all patients, based on PET and CT data. The Clinical Target
olume (CTV) was deﬁned as the GTV with a 5 mm margin incorpo-
ating microscopic disease. Subsequently, this CTV was  expanded
ith 1 cm to draw the PTV to incorporate the internal respiratory
otion and setup errors. A 3D conformal treatment plan was cal-
ulated on the PTV for all patients according to ICRU 50 guidelines.
osimetric values were calculated on the basis of dose-volume his-
ograms and dose distributions on each axial CT plan.
.3. Image analysis
The pre- and post-RT scans were analyzed and delineated using
he Siemens TrueD system (Version VC-30, Siemens A.G., Darm-
tad, Germany). On the pre-RT scan, the location and volume of the
DG uptake within the GTV were quantiﬁed using the threshold 34,
0, 50, 60 and 70% of the maximal SUV (SUVmax). On the post-RT
can, residual metabolic areas were deﬁned as FDG uptake higher
han in the aortic arch (SUV > SUVaorta) [18]. Within the residual
DG-positive areas, the high FDG uptake areas were deﬁned using
he thresholds 70, 80, and 90% of the tumour SUVmax. Using an
utomatic rigid-registration algorithm, based on mutual informa-
ion of the CT scans, the images of pre-RT scan were fused to the
ost-RT scan on the Siemens TrueD system. If the automatic reg-
stration showed a large deviation between the two  CT scans, the
mages were manually registered on the anatomy surrounding the
umour, e.g. the bony anatomy or large vessels. The contours of thencer 75 (2012) 73– 76
FDG-based thresholds on the post-RT scan were then transformed
to the pre-RT scan using the derived registration matrices. The con-
tours of the pre- and post-RT scan were exported from TrueD as
DICOM-RT structure sets. Using MATLAB (R2008b, The MathWorks
Inc, Natick, MA,  USA) the overlap fractions (OF) and volumes of
these contours were calculated. The overlap fraction was deﬁned
as the volume of overlap divided by the smallest volume [17,19].
By using this methodology it is possible to assess which threshold
on the pre-RT scan matches the residual disease on the post-RT
scan. All data are expressed as mean ± standard deviation (SD) and
range.
3. Results
3.1. Patient characteristics
To assess whether the location of the residual metabolic active
areas are located within the initial FDG-high uptake areas of the
primary tumour, two 18Fluorodeoxyglucose (FDG) PET-CT scans
were analyzed for all patients, one before radiotherapy (pre-RT)
and one after radiotherapy (post-RT). Of the twelve analyzed
patients, four patients showed no residual FDG uptake on the post-
RT scan and had a complete metabolic response. The other eight
patients showed residual FDG uptake within the primary tumour
(SUVmax > SUVaorta). One of these patients had a residue that was
not clearly distinguishable from the surrounding tissue due to FDG
avid inﬂammation. Therefore, seven patients remained for further
analysis.
3.2. Overlap of FDG-uptake before RT with residual areas
In Fig. 1, pre- and post-RT CT-PET images are shown of a repre-
sentative patient. The high FDG uptake areas (50% SUVmax) on the
pre-RT scan and the location of the residual areas on the post-RT
scan are shown. The residual areas are transposed to the pre-RT
scan, to show the overlap with 50% SUVmax high uptake area pre-
RT. Visual evaluation shows that the location of the residual areas
largely corresponds with the high FDG uptake areas pre-RT.
3.3. Overlap fractions of the FDG based thresholds
Fig. 2A depicts the overlap fractions and volumes of the
FDG uptake based thresholds within the primary tumour pre-
RT and post-RT. Here it is shown that the residual areas were
mainly located within the original GTV (OF = 93.7 ± 7.2% [range:
82.8–100]). Also, the 70%, 80% and 90% SUVmax high-uptake areas
within the residual areas showed a high overlap with the GTV
volume (OF = 93.5 ± 10.6% [range: 71.6–100%], 94.2 ± 11.5% [range:
69.6–100.0%], and 96.1 ± 10.2% [range: 73.0–100%] respectively).
Also, the pre-RT FDG uptake thresholds had a large overlap with
the residual areas. The 34% threshold pre-RT had an OF with the
residual areas of 86.9 ± 8.3% [range: 77.2–98.2%] and with the high-
uptake areas within the residue. Moreover, the same is true for the
pre-RT 40% and 50% SUVmax high FDG uptake area (OF = 77.4 ± 8.1%
[range: 67.7–89.9%] and OF = 67.9 ± 6.8% [range: 61.5–82.6%]). This
pre-RT 50% SUVmax area also largely corresponded with the 70–90%
SUVmax high-uptake areas within the residue.
3.4. Volumes of the FDG based thresholds
The volumes of the FDG based thresholds within the primary
tumour pre-RT and the post-RT thresholds are shown in Fig. 2B.
The FDG uptake areas (40–70% SUVmax) within the tumour on the
pre-RT scan were small compared to the GTV. The 40% SUVmax
encompassed 46.4 ± 14.4% [range: 23.0–66.5%] of the original GTV,
whereas this was  35.8 ± 11.8% [range: 19.6–54.7%] for the 50%
H.J.W.L. Aerts et al. / Lung Cancer 75 (2012) 73– 76 75
Fig. 1. Representative FDG-PET-CT images of a patient pre- and post-radiotherapy. The green lines indicate the 50% SUVmax FDG high uptake area pre-radiotherapy. The blue
lines  indicate the residual metabolic active areas post-radiotherapy, also transposed on the pre-radiotherapy scan. Visual evaluation shows a large correspondence between
t apy.
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UVmax, 23.9 ± 7.8% [range: 13.2–37.5%] for the 60% SUVmax, and
2.9 ± 5.1% [range: 8.2–23.3%] for the 70% SUVmax threshold.
The volume of the residual metabolic active areas on the post-
T scan was 14.6 ± 10.0% [range: 4.3–31.2%] of the pre-RT GTV
Fig. 2B). The relative volumes of the high uptake areas within the
esidual areas were very small: 11.9 ± 7.7% [range: 2.9–15.8%] for
he 70% SUVmax, 5.8 ± 4.9% [range: 0.8–15.6%] for the 80% SUVmax,
nd 1.9 ± 2.0% [range: 0.3–6.1%] for the 90% SUVmax threshold.
ig. 2. (A) Overlap-fractions (OF) of the pre-radiotherapy thresholds with the
ost-radiotherapy relative thresholds. The OF of the post-radiotherapy residual-
reas are indicated with the black-bars. The other bars indicate the OF with the
igh FDG-uptake (70–90%) areas within the residue. The data are expressed as
ean ± standard deviation (error-bars). (B) Volumes of the SUV thresholds of the
umour pre- and post-radiotherapy. All volumes are relative to the pre-radiotherapy
ross tumour volume (GTV). The data are expressed as mean ± standard deviation
error-bars).4. Discussion
In radiation oncology there is an growing interest to increase the
radiation dose towards more resistant tumour areas while reduc-
ing the dose to less resistant areas within the tumour [15]. In the
present study, we conﬁrmed in a prospective study the results that
the areas of high FDG uptake within the tumour before treatment
would allow identiﬁcation of residual metabolic-areas after ther-
apy [17]. Together with the results of the previous study, where
it was demonstrated that the high-uptake areas of FDG within the
tumour remained stable during a course of fractionated radiother-
apy for NSCLC [19], radiation boosting of these zones might be
beneﬁcial.
Here, we  have shown that the residual FDG uptake areas after
treatment largely corresponded to the 50% SUVmax within the
tumour before treatment, resulting in an overlap fraction of 68%.
This was similar with the previous obtained results [17], where
the overlap between these contours was  71%. The volume of the
residual FDG-positive areas was  on average 15% of the initial GTV
volume. The hotspot within the residual area (90% SUV) was  almost
completely within the pre-RT GTV (OF = 96%), and had a high over-
lap with the pre-radiotherapy 50%SUV threshold (OF > 74%). Based
on these results, we  conclude that residual metabolic active areas
within the tumour can be identiﬁed before treatment using an FDG-
PET-CT scan.
The pre-radiotherapy 50% SUVmax threshold had a volume that
encompassed 35% of pre-treatment GTV, similar with previous
results (39%). This makes the 50% SUVmax threshold value a suit-
able threshold for future radiation boosting target to improve local
control, not only because it yields good results, but also because it is
a simple, reproducible, and robust method between institutions. A
lower threshold would result in boosting the entire tumour and not
only the most resistant areas, whereas a too high threshold would
lead to only a few voxels to be treated, which is often impossible
due to organ motion or dose delivery constraints. However, the
most optimal threshold has to be determined in future studies.
A limitation of our study is that for the registration between
the pre and post-scans a rigid registration was performed, not
incorporating the non-rigid tissue changes possibly induced by
radiotherapy. This could be improved by using deformable regis-
tration techniques. However, these are difﬁcult to validate and the
reproducibility, especially in different institutes, is limited. Another
limitation of PET scanning is that due to partial volume effects
small areas of residual tumour could be missed. Also, for a wide
applicability of these results and before multi-center studies can be
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nitiated, a thorough standardisation and calibration of PET scan-
ing and radiotherapy delivery has to be performed [20–22].
. Conclusion
Our previous results were prospectively validated in an
ndependent dataset in another institute, showing that the resid-
al metabolic-active areas within the tumour after (sequential
hemo-) radiotherapy are located in the high FDG uptake areas
efore therapy and can be delineated. This information is the basis
or an ongoing randomized phase II trial to test the hypothesis that
igh FDG uptake areas reﬂect “radioresistance”, by redistribution
he dose according to pre-radiotherapy FDG uptake areas.
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